6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Oct 2026
- Reporting date
- 01 Oct 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,836 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 1-25 of 1,000 matching filings.
Per page
25
Current page
1
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 24 Sep 2026
- Reporting date
- 24 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 22 Sep 2026
- Reporting date
- 22 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
6-K
- Filing date
- 15 Sep 2026
- Reporting date
- 15 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA
- Filing date
- 15 Sep 2026
- Reporting date
- 15 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA
- Filing date
- 14 Sep 2026
- Reporting date
- 14 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC
- Filing date
- 14 Sep 2026
- Reporting date
- 14 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 11 Sep 2026
- Reporting date
- 11 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 10 Sep 2026
- Reporting date
- 10 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE
- Filing date
- 10 Sep 2026
- Reporting date
- 10 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 09 Sep 2026
- Reporting date
- 09 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 09 Sep 2026
- Reporting date
- 09 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
6-K
- Filing date
- 08 Sep 2026
- Reporting date
- 08 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Sep 2026
- Reporting date
- 01 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III
- Filing date
- 01 Sep 2026
- Reporting date
- 01 Sep 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 26 Aug 2026
- Reporting date
- 26 Aug 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 24 Aug 2026
- Reporting date
- 24 Aug 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN
- Filing date
- 24 Aug 2026
- Reporting date
- 24 Aug 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER
- Filing date
- 24 Aug 2026
- Reporting date
- 24 Aug 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 18 Aug 2026
- Reporting date
- 18 Aug 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 13 Aug 2026
- Reporting date
- 13 Aug 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 11 Aug 2026
- Reporting date
- 11 Aug 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 03 Aug 2026
- Reporting date
- 03 Aug 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 30 Jul 2026
- Reporting date
- 30 Jul 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE
- Filing date
- 28 Jul 2026
- Reporting date
- 28 Jul 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing